| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival
|
Italiano, A.
|
|
|
23 |
6 |
p. 1601-1607
|
artikel
|
| 2 |
Alcohol drinking and bladder cancer risk: a meta-analysis
|
Pelucchi, C.
|
|
|
23 |
6 |
p. 1586-1593
|
artikel
|
| 3 |
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
|
Aogi, K.
|
|
|
23 |
6 |
p. 1441-1448
|
artikel
|
| 4 |
A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
|
Chau, N.G.
|
|
|
23 |
6 |
p. 1562-1570
|
artikel
|
| 5 |
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
|
Vadhan-Raj, S.
|
|
|
23 |
6 |
p. 1640-1645
|
artikel
|
| 6 |
Aspirin and cancer risk: a quantitative review to 2011
|
Bosetti, C.
|
|
|
23 |
6 |
p. 1403-1415
|
artikel
|
| 7 |
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
|
Price, T.J.
|
|
|
23 |
6 |
p. 1531-1536
|
artikel
|
| 8 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
|
Zaman, K.
|
|
|
23 |
6 |
p. 1474-1481
|
artikel
|
| 9 |
Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study
|
Fauvet, R.
|
|
|
23 |
6 |
p. 1481-1487
|
artikel
|
| 10 |
Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy
|
Storey, D.J.
|
|
|
23 |
6 |
p. 1542-1549
|
artikel
|
| 11 |
Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS
|
Houot, R.
|
|
|
23 |
6 |
p. 1555-1561
|
artikel
|
| 12 |
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer
|
Cen, P.
|
|
|
23 |
6 |
p. 1503-1511
|
artikel
|
| 13 |
Dietary fiber and breast cancer risk: a systematic review and meta-analysis of prospective studies
|
Aune, D.
|
|
|
23 |
6 |
p. 1394-1402
|
artikel
|
| 14 |
Editorial board
|
|
|
|
23 |
6 |
p. ii-iii
|
artikel
|
| 15 |
Endocrine late sequelae in long-term survivors of childhood non-Hodgkin lymphoma
|
van Waas, M.
|
|
|
23 |
6 |
p. 1626-1632
|
artikel
|
| 16 |
Endocrine-responsive breast cancer special types: who cares?
|
Bonnefoi, H.
|
|
|
23 |
6 |
p. 1375-1377
|
artikel
|
| 17 |
Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party
|
D'Arena, G.
|
|
|
23 |
6 |
p. 1499-1502
|
artikel
|
| 18 |
Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials
|
You, B.
|
|
|
23 |
6 |
p. 1633-1639
|
artikel
|
| 19 |
Importance of gender in diffuse malignant peritoneal mesothelioma
|
Cao, C.
|
|
|
23 |
6 |
p. 1494-1498
|
artikel
|
| 20 |
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’
|
Mandala`, M.
|
|
|
23 |
6 |
p. 1416-1421
|
artikel
|
| 21 |
Internet use by cancer patients: should oncologists ‘prescribe’ accurate web sites in combination with chemotherapy? A survey in a Spanish cohort
|
López-Gómez, M.
|
|
|
23 |
6 |
p. 1579-1585
|
artikel
|
| 22 |
Large body size and sedentary lifestyle during childhood and early adulthood and esophageal squamous cell carcinoma in a high-risk population
|
Etemadi, A.
|
|
|
23 |
6 |
p. 1593-1600
|
artikel
|
| 23 |
Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic
|
Syed, B.M.
|
|
|
23 |
6 |
p. 1465-1471
|
artikel
|
| 24 |
Outcome of special types of luminal breast cancer
|
Colleoni, M.
|
|
|
23 |
6 |
p. 1428-1436
|
artikel
|
| 25 |
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial
|
Ferri, L.E.
|
|
|
23 |
6 |
p. 1512-1517
|
artikel
|
| 26 |
PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
|
Mao, C.
|
|
|
23 |
6 |
p. 1518-1525
|
artikel
|
| 27 |
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
|
Hayashi, H.
|
|
|
23 |
6 |
p. 1537-1541
|
artikel
|
| 28 |
Predicting and accounting for VTE in phase I cancer studies
|
Khorana, A.A.
|
|
|
23 |
6 |
p. 1373-1375
|
artikel
|
| 29 |
Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services
|
Klafke, N.
|
|
|
23 |
6 |
p. 1571-1578
|
artikel
|
| 30 |
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
|
Heng, D.Y.
|
|
|
23 |
6 |
p. 1549-1555
|
artikel
|
| 31 |
Proanthocyanidins and other flavonoids in relation to pancreatic cancer: a case–control study in Italy
|
Rossi, M.
|
|
|
23 |
6 |
p. 1488-1493
|
artikel
|
| 32 |
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study
|
Psyrri, A.
|
|
|
23 |
6 |
p. 1422-1427
|
artikel
|
| 33 |
Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points
|
Kay, A.
|
|
|
23 |
6 |
p. 1646-1651
|
artikel
|
| 34 |
Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance
|
van Oosterwijk, J.G.
|
|
|
23 |
6 |
p. 1617-1626
|
artikel
|
| 35 |
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer
|
Gori, S.
|
|
|
23 |
6 |
p. 1436-1441
|
artikel
|
| 36 |
Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects
|
Pemmaraju, N.
|
|
|
23 |
6 |
p. 1471-1474
|
artikel
|
| 37 |
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study
|
Maréchal, R.
|
|
|
23 |
6 |
p. 1525-1530
|
artikel
|
| 38 |
Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors: an uncontrolled experimental study with 24 weeks of follow-up
|
Haest, K.
|
|
|
23 |
6 |
p. 1449-1454
|
artikel
|
| 39 |
Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials
|
Whelan, J.S.
|
|
|
23 |
6 |
p. 1607-1616
|
artikel
|
| 40 |
Table of Contents
|
|
|
|
23 |
6 |
p. iv-vi
|
artikel
|
| 41 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer
|
LaBonte, M.J.
|
|
|
23 |
6 |
p. 1455-1464
|
artikel
|
| 42 |
The sequential use of endocrine treatment for advanced breast cancer: where are we?
|
Barrios, C.
|
|
|
23 |
6 |
p. 1378-1386
|
artikel
|
| 43 |
Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development
|
Decoster, L.
|
|
|
23 |
6 |
p. 1387-1393
|
artikel
|
Tijdschrift beschrijving